Range Financial Group LLC Invests $201,000 in DexCom, Inc. (NASDAQ:DXCM)

Range Financial Group LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,450 shares of the medical device company’s stock, valued at approximately $201,000.

Several other hedge funds also recently modified their holdings of the business. Stableford Capital II LLC lifted its stake in DexCom by 2.1% in the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after buying an additional 88 shares in the last quarter. D Orazio & Associates Inc. lifted its stake in DexCom by 0.8% in the fourth quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock valued at $1,534,000 after buying an additional 93 shares in the last quarter. Gulf International Bank UK Ltd lifted its stake in DexCom by 0.3% in the first quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock valued at $4,448,000 after buying an additional 93 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in DexCom by 10.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock valued at $133,000 after buying an additional 98 shares in the last quarter. Finally, Valley National Advisers Inc. lifted its stake in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Canaccord Genuity Group lifted their price objective on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. Redburn Atlantic assumed coverage on shares of DexCom in a report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price objective on the stock. Raymond James lifted their price objective on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Citigroup lifted their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Finally, UBS Group lifted their price objective on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $140.94.

DexCom Price Performance

NASDAQ:DXCM opened at $110.57 on Tuesday. DexCom, Inc. has a one year low of $74.75 and a one year high of $142.00. The company has a market cap of $43.97 billion, a P/E ratio of 71.34, a P/E/G ratio of 2.85 and a beta of 1.22. The firm’s fifty day moving average price is $124.81 and its two-hundred day moving average price is $125.90. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. The firm had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. Equities analysts expect that DexCom, Inc. will post 1.78 earnings per share for the current year.

Insider Activity

In other news, EVP Michael Jon Brown sold 2,624 shares of the business’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the sale, the executive vice president now owns 68,682 shares of the company’s stock, valued at $9,618,227.28. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, EVP Michael Jon Brown sold 2,624 shares of the company’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $140.04, for a total transaction of $367,464.96. Following the completion of the sale, the executive vice president now owns 68,682 shares of the company’s stock, valued at $9,618,227.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sadie Stern sold 427 shares of the company’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the sale, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 57,700 shares of company stock valued at $7,911,495. 0.30% of the stock is owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.